Abstract:Dear Editor, Erythrodermic psoriasis (EP) is an uncommon, severe variant of psoriasis characterized by widespread erythema of the skin, triggered by various factors, including pharmacological agents, infections, psychogenic stress, and alcohol. Here we report a unique case of EP triggered by B-cell chronic lymphocytic leukemia (CLL). A 60-year-old man with a 10-year history of chronic plaque psoriasis was referred for a sudden onset of erythroderma, which progressed rapidly to affect all body sites and persisted for 2 months. He also complained of fatigue, weight loss, and enlarged peripheral lymph nodes. At the initial presentation, generalized erythema with scaling was observed in more than 90% of the body surface area (Figure 1A). Skin biopsy showed features characteristic for psoriasis (Figure 1B). The infiltrating lymphocytes were predominantly CD4 positive and CD8 positive T cells, while CD20 positive B cells were scarce, excluding the leukemia skin infiltration (Figure 1C-F). Sustained elevations of peripheral white blood cells (13 040-14 270/μL, normal range 3500-9500/μL) and lymphocytes (8410-8460/μL, normal range 1100-3200/μL) were found during the past 2 months. Peripheral blood immunophenotype demonstrated monoclonal B-cell lymphocytosis with the expression of CD19, CD23, CD5, and kappa immunoglobulin light chain. A bone marrow biopsy confirmed the involvement of CLL. Therefore, EP with concurrent CLL, Binet stage B, was diagnosed. Topical steroid ointment was prescribed for psoriasis. Treatment for CLL was not initiated due to its low risk. The alleviation of his erythroderma was found to be along with a decrease in peripheral lymphocytes (Figure 1G). During follow-up, the severity of psoriatic lesions fluctuated with his lymphocyte count. The erythroderma relapsed when the lymphocyte count increased and subsided when it dropped to the normal range (Figure 1H). Oral low-dose methotrexate was applied to control the last flare-up in December, 2019. His skin disease and lymphocyte count gradually subsided and remained stable since then. EP is characterized by generalized erythema and scaling, with systemic symptoms of fever, lymphadenopathy, and weight changes. Generalized erythroderma may present suddenly or by worsening of chronic plaque psoriasis, triggered by infection, stress, alcoholism, and systemic illness (such as HIV and T-cell lymphoma). Chronic lymphocytic leukemia, a neoplasm composed of monomorphic small mature B cells, is a common leukemia in Western countries. Most patients are asymptomatic, and the diagnosis relies on routine blood analysis. Our case revealed a temporal relationship between psoriatic erythroderma and peripheral B-cell lymphocytosis caused by CLL. Similar phenomena had also been reported in patients who developed concurrent EP and B-cell lymphocytosis/leukemia. This close association suggests a pathogenic link underlying these two conditions. The pathogenesis of EP is not well understood; however, the disease may be associated with a predominant T helper 2 (Th2) phenotype. B cells are important during the Th2-type immune response and drive Th2 responses by instructing human dendritic cell maturation. Therefore, it is possible that the accumulation of circulating malignant B cells in our patient exacerbated the T cell inflammation in the skin and transformed plaque psoriasis to erythroderma via Th2 cytokines. Tumor necrosis factor-α (TNF-α), a well-known trigger for psoriasis, is another suspicious factor. TNF-α has been shown to be produced by leukemic lymphocytes in CLL patients and act as an autocrine and paracrine growth factor. The elevated autocrine TNF-α may contribute to the exacerbation of psoriasis. Therefore, antiinflammatory therapies, including TNF inhibitors, may serve as potential therapeutic options for this situation, as reported previously. This case provides new information about the triggers for EP. B-cell malignancy should be considered in patients with exacerbated psoriasis and peripheral lymphocytosis.

Anemia and Thrombocytosis Associated with Erythrodermic Psoriasis Successfully Treated with Ixekizumab: A Case Report

Effect of Ixekizumab on Enthesitis-related arthritis non-responsive to anti-TNF treatment, a case report

Clinical and immunological phenotype switch to prurigo nodularis in a patient receiving ixekizumab for treating psoriasis: a case report

Usefulness of Tocilizumab for Treating Rheumatoid Arthritis with Myelodysplastic Syndrome

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab

Updates on the Treatment of Erythrodermic Psoriasis

Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report

Metabolic Profiling Reveals Interleukin-17A Monoclonal Antibody Treatment Ameliorate Lipids Metabolism with the Potentiality to Reduce Cardiovascular Risk in Psoriasis Patients

Ixekizumab: an alternative for HIV-positive psoriasis patients

Erythrodermic Psoriasis Precipitated by B‐cell Chronic Lymphocytic Leukemia

Crohn's Disease Exacerbated by IL-17 Inhibitors in Patients with Psoriasis: a Case Report.

Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.

Cerebral Tumefactive Inflammatory Lesion Occurrence During Ixekizumab Treatment in a Patient With Active Psoriatic Arthritis

Multiple Mucosal Ulcers Induced by Ixekizumab: A Case Report

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

P26 A life threatening case of Von Zumbusch psoriasis

Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation

Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab

Biologic anti-IL17 drugs in erythrodermic psoriasis

IgA Nephropathy Associated with Erythrodermic Psoriasis A Case Report